{
    "root": "2ae0ec4d-2a17-41f3-9506-660775ee9092",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gomekli",
    "value": "20250227",
    "ingredients": [
        {
            "name": "MIRDAMETINIB",
            "code": "86K0J5AK6M"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "DEHYDRATED ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "GRAPE",
            "code": "6X543N684K"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        }
    ],
    "indications": "gomekli indicated treatment adult pediatric patients 2 years age older neurofibromatosis type 1 ( nf1 ) symptomatic plexiform neurofibromas ( pn ) amenable complete resection [ ( 14 ) ] .",
    "contraindications": "recommended gomekli 2 mg/m 2 orally twice daily , without food , first 21 days 28-day cycle . continue treatment gomekli disease progression unacceptable toxicity . ( 2 )",
    "warningsAndPrecautions": "supplied gomekli capsules supplied follows : capsule strength capsule description package configuration ndc 1 mg light green body cap “ mir 1 mg ” printed cap white ink . bottle 42 capsules 82448-130-42 2 mg white body blue green cap “ mir 2 mg ” printed cap white ink . bottle 42 capsules 82448-260-42 bottle 84 capsules 82448-260-84 gomekli tablets oral suspension supplied follows : tablet strength tablet description package configuration ndc 1 mg white off-white , oval , grape flavored tablet , debossed “ ” one side . bottle 42 tablets 82448-134-42 bottle 84 tablets 82448-134-84 storage handling store capsules tablets oral suspension 20°c 25°c ( 68°f 77°f ) . excursions permitted 15°c 30°c ( 59°f 86°f ) . usp controlled room temperature . protect light .",
    "adverseReactions": "none .",
    "indications_original": "GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection [see \n                     \n                        Clinical Studies (14)\n                     \n                     ].",
    "contraindications_original": "The recommended dosage of GOMEKLI is 2 mg/m 2 orally twice daily, with or without food, for the first 21 days of each 28-day cycle. Continue treatment with GOMEKLI until disease progression or unacceptable toxicity. ( 2 )",
    "warningsAndPrecautions_original": "How\n                      \n                     supplied\n                  \n                  \n                     GOMEKLI\n                      \n                     Capsules\n                      \n                     are\n                      \n                     supplied\n                      \n                     as\n                      \n                     follows:\n                  \n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Capsule Strength\n                           \n                           \n                              Capsule\n                               \n                              Description\n                           \n                           \n                              Package Configuration\n                           \n                           \n                              NDC\n                           \n                        \n                        \n                           1 mg\n                           Light green body and cap with “MIR 1 mg” printed on the cap in white ink.\n                           Bottle of 42 capsules\n                           82448-130-42\n                        \n                        \n                           \n                              2 mg\n                           White body and a blue green cap with “MIR 2 mg” printed on the cap in white ink.\n                           Bottle of 42 capsules\n                           82448-260-42\n                        \n                        \n                           \n                           \n                           Bottle of 84 capsules\n                           82448-260-84\n                        \n                     \n                  \n                  \n                     GOMEKLI\n                      \n                     Tablets\n                      \n                     for\n                      \n                     Oral\n                      \n                     Suspension\n                      \n                     are\n                      \n                     supplied\n                      \n                     as\n                      \n                     follows:\n                  \n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Tablet Strength\n                           \n                           \n                              Tablet\n                               \n                              Description\n                           \n                           \n                              Package Configuration\n                           \n                           \n                              NDC\n                           \n                        \n                        \n                           \n                              1 mg\n                           \n                              White to off-white, oval, grape flavored tablet, debossed with “S” on one side.\n                           Bottle of 42 tablets\n                           82448-134-42\n                        \n                        \n                           \n                           \n                           Bottle of 84 tablets\n                           82448-134-84\n                        \n                     \n                  \n                  \n                     Storage\n                      \n                     and\n                      Handling\n                  \n                  Store capsules and tablets for oral suspension at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature. Protect from light.",
    "adverseReactions_original": "None."
}